Item 5.02. Departure of Directors or Certain O?cers; Election of Directors; Appointment of Certain O?cers; Compensatory Arrangements of Certain O?cers.

On January 13, 2023, the board of directors (the "Board") of Qualigen Therapeutics, Inc. (the "Company"), as part of certain cost-cutting measures, approved a temporary 20% reduction to the base salaries of all executive officers of the Company, including Michael Poirier, the Company's Chief Executive Officer, Christopher Lotz, the Company's Chief Financial Officer, Amy Broidrick, the Company's President and Chief Strategy Officer (also a named executive officer), Shishir Sinha, the Company's Chief Operating Officer and Senior Vice President, Diagnostics, and Tariq Arshad, the Company's Chief Medical Officer (also a named executive officer), effective immediately. The amendments to such executive officers' executive employment agreements or offer letters, as applicable, will be filed as exhibits to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2022.

As part of such cost cutting measures, on January 17, 2023, the Company provided notice to Mr. Sinha that his employment with the Company would be terminated effective February 16, 2023 (the "Effective Date").

Ms. Broidrick's title will become President, Chief Strategy and Operating Officer, effective as of the Effective Date. Ms. Broidrick's full biography and other information required by Item 5.02(c) of Form 8-K are included in the Company's proxy statement for its 2022 Annual Meeting of Stockholders, filed with the U.S. Securities and Exchange Commission on July 13, 2022 under the section titled "Board of Directors and Corporate Governance", and such information is incorporated herein by reference.




Item 8.01. Other Events.

As part of the cost-cutting measures described in Item 5.02 of this Current Report on Form 8-K, the Board also approved a temporary 20% reduction to the non-employee directors' annual cash compensation, and the elimination of the Company's position of Vice President and Chief Scientific Officer, currently held by Wajdi Abdul-Ahad, along with several other non-executive positions, effective January 17, 2023.

© Edgar Online, source Glimpses